CytomX Therapeutics (CTMX) announced that it has entered into a clinical trial collaboration and supply agreement with Merck (MRK) for CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy Keytruda.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- CytomX Therapeutics upgraded to Buy from Hold at Jefferies
- Biotech Alert: Searches spiking for these stocks today
- CytomX Therapeutics extends rally, shares up 218% to $5.19
- BMO sees CytomX rallying after ‘surprise’ data announcement
